After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower ...
Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback